In the December 2014 issue of The Antitrust Source, John Woodbury comments on a working paper co-authored by two CRA economists, José Azar and Isabel Tecu (as well as Martin Schmalz) that examines the effect institutional investors may have on softening competition downstream. To read the article, click the link below.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...